XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
GENERAL
 6 Months Ended
Dec. 31, 2012
GENERAL [Abstract]  
GENERAL
NOTE 1:-GENERAL
 
 
a.
Pluristem Therapeutics Inc., a Nevada corporation, was incorporated on May 11, 2001. Pluristem Therapeutics Inc. has a wholly owned subsidiary, Pluristem Ltd. (the "Subsidiary"), which is incorporated under the laws of the State of Israel. Pluristem Therapeutics Inc. and the Subsidiary are referred to as the "Company".
 
 
b.
The Company is a bio-therapeutics company developing standardized cell therapy products from human placenta for the treatment of multiple disorders. The Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company's accumulated losses aggregated to $74,232 through December 31, 2012 and the Company incurred a net loss of $8,485 for the six months ended December 31, 2012. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis.
 
The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation ("United Therapeutics") agreement, and from grants to support its R&D activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.